cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Agios Pharmaceuticals Inc
7 own
14 watching
Current Price
$30.2
$0.02
(0.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,657.8M
52-Week High
52-Week High
34.76
52-Week Low
52-Week Low
16.75
Average Volume
Average Volume
0.49M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
1.6274
iconMarket Capitalization1,657.8M
icon52-Week High34.76
icon52-Week Low16.75
iconAverage Volume0.49M
iconDividend Yield--
iconP/E Ratio1.6274
What does the Agios Pharmaceuticals Inc do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Agios Pharmaceuticals Inc make?
News & Events about Agios Pharmaceuticals Inc.
Globe Newswire
26days ago
Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency Driving toward two additional PYRUKYND indications, with potential FDA approvals in thalassemia in 2025 and...
Globe Newswire
1month ago
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st AnnualJ.P. Morgan Healthcare ConferenceonWednesday...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap ...
Zolmax
3 months ago
DekaBank Deutsche Girozentrale bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO Get Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,000 shares of the biopharmaceutical companys stock, ...
Globe Newswire
3 months ago
Long-term Data for PYRUKYND (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement in Hemoglobin, Markers of Hemolysis and Other Disease Impacts New Data from Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts of ...
Frequently Asked Questions
Frequently Asked Questions
What is Agios Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Agios Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Agios Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Agios Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Agios Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Agios Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Agios Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Agios Pharmaceuticals Inc?
plus_minus_icon
What percentage is Agios Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Agios Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$30.2
$0.02
(0.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.92
$-0.28 (-0.68 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.66
$-0.07 (-4.05 %)
Veracyte, Inc.
Veracyte, Inc.
$26.67
$-1.22 (-4.37 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.92
$-0.28 (-0.68 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.66
$-0.07 (-4.05 %)
Veracyte, Inc.
Veracyte, Inc.
$26.67
$-1.22 (-4.37 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00